Chicago buyout firm Thoma Bravo agreed to take Limerick‑based Kneat private in an all‑cash deal valuing the life‑sciences validation software maker at about C$650M.

FDA found Bacillus cereus and other quality lapses at Medline's Waukegan drug plant; the agency ordered independent risk assessments and remediation timelines.

Chicago’s Tempus won FDA clearance to run its xT CDx test without matched normal samples, a label expansion the company says will broaden use and affect reimbursement.

Chicago's Architect is pushing exchange‑traded futures on GPU and DRAM prices, setting up competition with CME and ICE. The move could make compute costs a tradable asset.

VectorBuilder plans a $50M, 35,000‑sq‑ft R&D lab on Chicago’s South Side, targeting a 2027 opening and expanding the city’s CDMO capacity.

A South Side woman underwent a rare quadruple-organ transplant at UChicago Medicine, receiving both lungs, a kidney and a liver from a single donor in a marathon operation.

A Northwestern study shows montelukast reprograms tumor-supporting immune cells and restores checkpoint-inhibitor response in lab models.

A Lancet‑published consensus has renamed PCOS to PMOS to emphasize hormonal and metabolic causes. Patient groups are split as the three‑year roll‑out begins.

Richard and Gayle Landuyt pledged more than $20 million to rename the University of Illinois entrepreneurship hub and build a Chicago presence to speed startups. The gift will fund leadership, prizes and programming across campus and downtown.

Rush performed the first U.S. thumb joint replacement using the TOUCH CMC 1 prosthesis, a ball‑and‑socket implant designed to restore pinch and speed recovery. The device is beginning to roll out to other U.S. centers.

UChicago professors propose scaling a hands‑on "Tools of Thought" apprenticeship that pairs City Colleges students with Chicago firms to teach the nonroutine skills AI can’t replace.

Interim REMAIN‑1 results suggest a one‑time endoscopic "gut reset" can help maintain weight after stopping GLP‑1 drugs. Topline pivotal data are expected in Q4 2026.

Veil Global sued Norton Rose Fulbright in Cook County, alleging the firm failed to pay a USPTO fee and cost the company licensing value; it seeks at least $100 million.